Report cover image

Global Oncology Biosimilars Market

Publisher BCC Research
Published Dec 31, 2025
Length 173 Pages
SKU # WA20694390

Description

Report Scope

The report examines and segments the global oncology biosimilars market by indication, drug class, route of administration and distribution channel. It also provides insights into key emerging trends and potential growth drivers. The study focuses on indications such as breast, lung and blood cancers and others. By drug class, it focuses on granulocyte colony-stimulating factors, monoclonal antibodies, hematopoietic agents and others. By route of administration, the focus is on intravenous, subcutaneous and others. The report also examines hospital, retail and online pharmacies and others by distribution channel.

Included is a regional analysis of North America, Europe, Asia-Pacific, South America and the Middle East and Africa that evaluates the impact of AI adoption on the oncology biosimilars industry and market dynamics, including drivers, challenges and emerging trends, while highlighting product and performance enhancement innovations. The study concludes with an analysis of major companies in the market and their offerings.

It includes global revenue ($ million) for the base year 2024, estimated for 2025 and data for the forecast period 2026 through 2030.

Report Includes
  • 140 data tables and 40 additional tables
  • In-depth analysis of the global market for oncology biosimilar drugs
  • Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
  • Estimates of the current market size and revenue prospects of the global market, along with a market share analysis by disease indication (cancer type), drug class, route of administration, distribution channel and region
  • Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
  • Impact analysis of the U.S. tariffs on the market for biologics used in cancer treatment and supportive care
  • Insights derived from Porter’s Five Forces model, as well as global supply chain analyses
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
  • A relevant patent analysis, featuring key granted and published patents
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
  • Profiles of the leading companies, including Samsung Bioepis, Sandoz Group AG, Celltrion Inc., Amgen Inc., and Biocon Biologics Ltd.


Companies Mentioned

Accord Healthcare
Alvotech
Amgen Inc.
Amneal Pharmaceuticals Llc.
Apotex Inc.
Biocad
Biocon Biologics Ltd.
Celltrion Inc.
Fresenius Kabi Ag
Pfizer Inc.
Samsung Bioepis
Sandoz Group Ag
Teva Pharmaceutical Industries Ltd.
Viatris Inc.

Table of Contents

173 Pages
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
Chapter 2 Market Overview
Current Market Overview
Future Outlook
Analysis of Macroeconomic Factors
Impact of U.S. Tariffs on the Market
Impact of the Ukraine-Russia War
Economic Growth and Development
Demographic Shifts
Healthcare Expenditure Trends
Inflation and Currency Fluctuations
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Overview
Market Drivers
Surge in Global Cancer Incidence
Expiration of Blockbuster Biologic Patents
Need for Cost-Effective Cancer Therapies
Demand for Targeted and Supportive Oncology Treatments
Market Restraints
Regulatory Complexity and Approval Hurdles
Patent Challenges and Legal Barriers
Pharmacy Benefit Manager Practices
Market Opportunities
Expansion into Emerging Markets
Development of Novel Biosimilar Combinations and Specialty Formulations
Chapter 4 Regulatory Landscape
Regulatory Framework
U.S.
Europe
India
Australia
Japan
Chapter 5 Emerging Technologies and New Developments
Overview
Emerging Technologies
Advanced Cell Line Engineering
Artificial Intelligence and Machine Learning in Biosimilar Development
Gene Editing and Synthetic Biology Approaches
Modular and Single-Use Bioreactors
Patent Analysis
Key Takeaways
Patents, by Year
Patents, by Leading Jurisdiction
Patents, by Leading Inventor
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Oncology Biosimilars Market, by Indication
Key Takeaways
Breast Cancer
Lung Cancer
Blood Cancer
Others
Global Oncology Biosimilars Market, by Drug Class
Key Takeaways
Granulocyte Colony-Stimulating Factor
Monoclonal Antibodies
Hematopoietic Agents
Others
Global Oncology Biosimilars Market, by Route of Administration
Key Takeaways
Intravenous
Subcutaneous
Others RoA
Global Oncology Biosimilars Market, by Distribution Channel
Key Takeaways
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Geographic Breakdown
Global Oncology Biosimilars Market, by Region
Key Takeaways
North America
Europe
Asia-Pacific
Middle East and Africa
South America
Chapter 7 Competitive Intelligence
Industry Structure
Company Share Analysis for Oncology Biosimilars Market
Strategic Analysis
Chapter 8 Sustainability in the Oncology Biosimilars Market: ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives of the Oncology Biosimilars Industry
Concluding Remarks
Chapter 9 Appendix
Methodology
Abbreviations
Company Profiles
ACCORD HEALTHCARE
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
APOTEX INC.
BIOCAD
BIOCON BIOLOGICS LTD.
CELLTRION INC.
FRESENIUS KABI AG
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.
Emerging Start-ups/Market Disruptors

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us